Foresite Capital

Foresite Capital is an investment firm that aims to transform healthcare by funding visionaries with the courage, data-driven insights and experience to lead the next wave of healthcare companies.

Foresite Capital seeks to address areas of great unmet medical need by funding and supporting transformative healthcare businesses.

Foresite Capital was founded in 2011 by Jim Tananbaum. The company is headquartered in San Francisco, California and New York City.


Foresite uses a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare. Foresite understands the unique business models in healthcare and works closely with the firm’s portfolio companies at all stages of their lifecycle.


Foresite Capital launched, Foresite Labs in October 2019 to found, build and scale life sciences companies at the intersection of healthcare and data science. Foresite Labs was founded to provide expanded capabilities in company creation.


Foresite Capital has raised a $173M fund to further invest in companies launched by Foresite Labs. The fund comes on the heels of several major milestones for Foresite Capital including the announcement of its $969 million Fund V and investments in Foresite Labs incubated companies Interline Therapeutics, Alumis and TenSixteen Bio.


Foresite has $4B in assets under management and has invested over hundred companies. Some of its portfolio includes 10x Genomics, Element Biosciences, Lyell Immunopharma, Inscripta, Relay Therapeutics, Gemini Therapeutics etc.



  • Year founded: 2011
  • Funding Info: NA
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: Asset Under Management: $4B as of Mar 03, 2022
  • City/Town: San Francisco
  • State: California
  • Country: United States
Related businesses